511 related articles for article (PubMed ID: 31619522)
21. Bone Morphogenetic Protein-2 Promotes Osteoclasts-mediated Osteolysis via Smad1 and p65 Signaling Pathways.
Miao X; Yuan J; Wu J; Zheng J; Zheng W; Wang F; Wang C; Li X; Liu S; Shi Z; Li J
Spine (Phila Pa 1976); 2021 Feb; 46(4):E234-E242. PubMed ID: 33156278
[TBL] [Abstract][Full Text] [Related]
22. Oxidation derivative of (-)-epigallocatechin-3-gallate (EGCG) inhibits RANKL-induced osteoclastogenesis by suppressing RANK signaling pathways in RAW 264.7 cells.
Xu H; Liu T; Li J; Xu J; Chen F; Hu L; Zhang B; Zi C; Wang X; Sheng J
Biomed Pharmacother; 2019 Oct; 118():109237. PubMed ID: 31376653
[TBL] [Abstract][Full Text] [Related]
23. Bone morphogenic protein 2 directly enhances differentiation of murine osteoclast precursors.
Jensen ED; Pham L; Billington CJ; Espe K; Carlson AE; Westendorf JJ; Petryk A; Gopalakrishnan R; Mansky K
J Cell Biochem; 2010 Mar; 109(4):672-82. PubMed ID: 20039313
[TBL] [Abstract][Full Text] [Related]
24. Smad1/5 and Smad4 expression are important for osteoclast differentiation.
Tasca A; Stemig M; Broege A; Huang B; Davydova J; Zwijsen A; Umans L; Jensen ED; Gopalakrishnan R; Mansky KC
J Cell Biochem; 2015 Jul; 116(7):1350-60. PubMed ID: 25711193
[TBL] [Abstract][Full Text] [Related]
25. Zinc inhibits osteoclast differentiation by suppression of Ca2+-Calcineurin-NFATc1 signaling pathway.
Park KH; Park B; Yoon DS; Kwon SH; Shin DM; Lee JW; Lee HG; Shim JH; Park JH; Lee JM
Cell Commun Signal; 2013 Oct; 11():74. PubMed ID: 24088289
[TBL] [Abstract][Full Text] [Related]
26. Adenylate cyclase and calmodulin-dependent kinase have opposite effects on osteoclastogenesis by regulating the PKA-NFATc1 pathway.
Yoon SH; Ryu Jy; Lee Y; Lee ZH; Kim HH
J Bone Miner Res; 2011 Jun; 26(6):1217-29. PubMed ID: 21611964
[TBL] [Abstract][Full Text] [Related]
27. Bone Morphogenetic Protein-2 (BMP-2) Activates NFATc1 Transcription Factor via an Autoregulatory Loop Involving Smad/Akt/Ca2+ Signaling.
Mandal CC; Das F; Ganapathy S; Harris SE; Choudhury GG; Ghosh-Choudhury N
J Biol Chem; 2016 Jan; 291(3):1148-61. PubMed ID: 26472929
[TBL] [Abstract][Full Text] [Related]
28. Flunarizine inhibits osteoclastogenesis by regulating calcium signaling and promotes osteogenesis.
Kim HJ; Lee J; Lee GR; Kim N; Lee HI; Kwon M; Kim NY; Park JH; Kang YH; Song HJ; Kim T; Shin DM; Jeong W
J Cell Physiol; 2021 Dec; 236(12):8239-8252. PubMed ID: 34192358
[TBL] [Abstract][Full Text] [Related]
29. Stimulation of osteoclast formation by RANKL requires interferon regulatory factor-4 and is inhibited by simvastatin in a mouse model of bone loss.
Nakashima Y; Haneji T
PLoS One; 2013; 8(9):e72033. PubMed ID: 24039733
[TBL] [Abstract][Full Text] [Related]
30. Pueraria lobate Inhibits RANKL-Mediated Osteoclastogenesis Via Downregulation of CREB/PGC1β/c-Fos/NFATc1 Signaling.
Park KH; Gu DR; Jin SH; Yoon CS; Ko W; Kim YC; Lee SH
Am J Chin Med; 2017; 45(8):1725-1744. PubMed ID: 29121799
[TBL] [Abstract][Full Text] [Related]
31. Inhibition of RANKL-induced osteoclastogenesis by (-)-DHMEQ, a novel NF-kappaB inhibitor, through downregulation of NFATc1.
Takatsuna H; Asagiri M; Kubota T; Oka K; Osada T; Sugiyama C; Saito H; Aoki K; Ohya K; Takayanagi H; Umezawa K
J Bone Miner Res; 2005 Apr; 20(4):653-62. PubMed ID: 15765185
[TBL] [Abstract][Full Text] [Related]
32. Siglec-15 regulates osteoclast differentiation by modulating RANKL-induced phosphatidylinositol 3-kinase/Akt and Erk pathways in association with signaling Adaptor DAP12.
Kameda Y; Takahata M; Komatsu M; Mikuni S; Hatakeyama S; Shimizu T; Angata T; Kinjo M; Minami A; Iwasaki N
J Bone Miner Res; 2013 Dec; 28(12):2463-75. PubMed ID: 23677868
[TBL] [Abstract][Full Text] [Related]
33. Inhibition of receptor activator of nuclear factor-κB ligand (RANKL)-induced osteoclast formation by pyrroloquinoline quinine (PQQ).
Odkhuu E; Koide N; Haque A; Tsolmongyn B; Naiki Y; Hashimoto S; Komatsu T; Yoshida T; Yokochi T
Immunol Lett; 2012 Feb; 142(1-2):34-40. PubMed ID: 22193059
[TBL] [Abstract][Full Text] [Related]
34. α-Linolenic Acid Inhibits Receptor Activator of NF-κB Ligand Induced (RANKL-Induced) Osteoclastogenesis and Prevents Inflammatory Bone Loss via Downregulation of Nuclear Factor-KappaB-Inducible Nitric Oxide Synthases (NF-κB-iNOS) Signaling Pathways.
Song J; Jing Z; Hu W; Yu J; Cui X
Med Sci Monit; 2017 Oct; 23():5056-5069. PubMed ID: 29061958
[TBL] [Abstract][Full Text] [Related]
35. Mechanisms involved in enhancement of osteoclast formation by activin-A.
Kajita T; Ariyoshi W; Okinaga T; Mitsugi S; Tominaga K; Nishihara T
J Cell Biochem; 2018 Aug; 119(8):6974-6985. PubMed ID: 29737562
[TBL] [Abstract][Full Text] [Related]
36. BMP type I receptor ALK2 is required for angiotensin II-induced cardiac hypertrophy.
Shahid M; Spagnolli E; Ernande L; Thoonen R; Kolodziej SA; Leyton PA; Cheng J; Tainsh RE; Mayeur C; Rhee DK; Wu MX; Scherrer-Crosbie M; Buys ES; Zapol WM; Bloch KD; Bloch DB
Am J Physiol Heart Circ Physiol; 2016 Apr; 310(8):H984-94. PubMed ID: 26873969
[TBL] [Abstract][Full Text] [Related]
37. Bone morphogenetic proteins.
Chen D; Zhao M; Mundy GR
Growth Factors; 2004 Dec; 22(4):233-41. PubMed ID: 15621726
[TBL] [Abstract][Full Text] [Related]
38. DOK3 Modulates Bone Remodeling by Negatively Regulating Osteoclastogenesis and Positively Regulating Osteoblastogenesis.
Cai X; Xing J; Long CL; Peng Q; Humphrey MB
J Bone Miner Res; 2017 Nov; 32(11):2207-2218. PubMed ID: 28650106
[TBL] [Abstract][Full Text] [Related]
39. Neogambogic Acid Suppresses Receptor Activator of Nuclear Factor κB Ligand (RANKL)-Induced Osteoclastogenesis by Inhibiting the JNK and NF-κB Pathways in Mouse Bone Marrow-Derived Monocyte/Macrophages.
Jin G; Wang FF; Li T; Jia DD; Shen Y; Xu HC
Med Sci Monit; 2018 Apr; 24():2569-2577. PubMed ID: 29698379
[TBL] [Abstract][Full Text] [Related]
40. Estrogen-related receptor γ negatively regulates osteoclastogenesis and protects against inflammatory bone loss.
Kim HJ; Kim BK; Ohk B; Yoon HJ; Kang WY; Cho S; Seong SJ; Lee HW; Yoon YR
J Cell Physiol; 2019 Feb; 234(2):1659-1670. PubMed ID: 30076703
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
